Gut Microbiome 4

VIVA Gut Microbiome and Cancer Education Webinar Series:

Gut Microbiome and Cancer Recovery

5 Nov 2022 (Saturday) |  08:30 - 09:30 (UTC+8 | SGT)  |  Check your Time Zone

Register Now homeimprovment.info

Programme Synopsis


The gut microbiota has been implicated in cancer and shown to modulate anticancer drug efficacy. Altered gut microbiota is associated with resistance to chemo drugs or immune checkpoint inhibitors (ICIs), whereas supplementation of distinct bacterial species restores responses to the anticancer drugs. Accumulating evidence has revealed the potential of modulating the gut microbiota to enhance the efficacy of anticancer drugs. Regardless of the valuable findings by preclinical models and clinical data of patients with cancer, a more thorough understanding of the interactions of the microbiota with cancer therapy helps researchers identify novel strategy for  more effective treatment and reduce treatment complication. We will discuss the scientific evidence on the role of gut microbiota in cancer treatment, and highlight the latest knowledge and technologies leveraged to target specific bacteria that contribute to tumourigenesis. We will also discuss the limitations of current microbiome research in the context of cancer treatment and ongoing efforts to overcome these challenges.

 

SPEAKER 


Michelle Hermiston

A/Prof Joanne Ngeow

BMedSci, MBBS, FRCP, MPH, FAMS
Assoc Prof, Lee Kong Chian School of Medicine
Nanyang Technological University, Singapore
Senior Consultant, Division of Medical Oncology
National Cancer Centre Singapore

 

Dr Joanne Ngeow, BMedSci, MBBS, FRCP, MPH is Senior Consultant, Division of Medical Oncology at the National Cancer Centre Singapore and Associate Professor (Genomic Medicine) at the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore. Dr Ngeow currently heads the Cancer Genetics Service at the National Cancer Centre Singapore with an academic clinical interest in hereditary cancer syndromes and translational clinical cancer genetics. Dr Ngeow is funded by the National Medical Research Council Clinician Scientist Award and Ministry of Health to explore how gene-environmental interactions predisposes to cancer initiation and progression and the implementation of genomics into routine clinical care. Dr Ngeow is one of the Principal Investigators of the Health for Life in Singapore Study (HELIOS), a state-of-the-art multi-ethnic population cohort study.


TC Quah

MODERATOR:

A/Prof Sunny Wong

Associate Professor of Nutrition, Digestion and Metabolism and Assistant Dean, Academic Medicine, Lee Kong Chian School of Medicine
Associate Professor, Lee Kong Chian School of Medicine
Nanyang Technological University
Singapore

Dr Sunny Wong is a clinician-scientist and an Associate Professor at the Lee Kong Chian School of Medicine, Nanyang Technological University Singapore. He received his MBChB with Honors at the Chinese University of Hong Kong, and his DPhil in University of Oxford on human genetics and infectious diseases. He completed his clinical training in gastroenterology and endoscopy in the Prince of Wales Hospital Hong Kong. His main research interest is on gut microbiome, investigating the host-microbe interaction in digestive and metabolic diseases, and exploring this for discovery of novel biomarkers and therapeutics. He has won several awards, including the Asia Pacific Digestive Week Emerging Leaders Lectureship (2021), the Sir David Todd Lectureship (2020), the Lo Ying Shek Chi Wai Foundation Meritorious Research Award (2020), and the Croucher Foundation Award (2014). He has published over 160 peer-reviewed articles including papers in Nature Genetics, Nature Communications, Gastroenterology and Gut. He is currently an Associate Editor for the Journal of Gastroenterology and Hepatology.